智通财经网·2026-01-09 14:20Core Viewpoint - Revolution Medicines (RVMD.US) has seen a significant pre-market increase of nearly 15%, following a cumulative rise of 35% over the past two trading days, amid reports of potential acquisition discussions with Merck (MRK.US) [1] Group 1: Acquisition Talks - Merck is reportedly in discussions to acquire Revolution Medicines, with the proposed transaction price estimated between $28 billion and $32 billion [1] - If the acquisition is finalized, it would mark one of the largest pharmaceutical industry deals since Pfizer (PFE.US) acquired Seagen for $43 billion at the end of 2023 [1] Group 2: Other Acquisition Interest - AbbVie (ABBV.US) was also reported to be in "deep" negotiations to acquire Revolution Medicines, with a potential valuation exceeding $20 billion for the company, which currently has no products on the market [1] - However, AbbVie later clarified that it is not in negotiations to acquire Revolution Medicines [1]